Article
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer.
Breast cancer research : BCR - 31 Jan 2026
Shen Sherry, Teysir Jimmitti, Safonov Anton, Bromberg Maria, Chen Yuan, Ahmed Mehnaj, Razavi Pedram, Jhaveri Komal
Abstract excerpt
BACKGROUND: Everolimus, an mTOR inhibitor, is FDA-approved with endocrine therapy (ET) for hormone receptor-positive (HR+)/HER2- MBC regardless of PI3K/AKT/mTOR pathway mutation status. Alpelisib, a PI3K inhibitor, is FDA-approved with fulvestrant for PIK3CA-mutant HR+/HER2- MBC. The efficacy and safety of sequential treatment with these pathway inhibitors is not well described. METHODS: This single-center...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.